Benefits at a glance

  • Small MOQs (50 packs) 
  • Reliable Supplier 
  • Limited Sources

Product details


Chronic myelogenous leukemia (CML)


100 mg + 400 mg + 500 mg

Dosage form

Film coated tablet



Dossier expected



95 Mio. € (IQVIA 2021 – EU)


  • Development Kick-off
  • Formulation Development
  • Prototype
  • Pilot BE
  • Scale Up
  • Pivotal BE
  • 6 M Stability
  • Dossier
  • EU-Approval


With our Bosutinib-Dossier, we make an exciting addition to our high-potent Oncology-portfolio.

With the product being backed by a reliable and established supply chain, we can also supply very small MoQs, with SKUs as little as 50 packs.

Zone IVb data will also be included in the stability program, therefor we can offer the product without any geographical restrictions and for large territories.

With Chronic myelogenous leukemia being responsible for approximately 20 % of leukemia cases, our product cannot only help a large number of people get adequate access to an effective treatment, but also can unlock a large market potential with sustained growth on a very high level.


Your Contact

Heike Sagi

Heike Sagi

Business Development & Licensing
Senior Director

Midas Pharma GmbH
Rheinstraße 49
55218 Ingelheim
  • Disclaimer

    The exploitation, including the development, sale and offer for sale of products and related processes is performed by Midas only in those territories where permissible by applicable patent law in particular, but not limited to EC Directive 2001/83 EC, Article 10, as amended by EC Directive 2004/27 EC. This document, therefore, does not and shall not constitute an offer for sale for the product in territories where an offer for sale or sale is not permissible by law. Midas expressly disclaims any liability for the information provided in this document as well as for damages resulting from or arising out of the use of the product and related process for purposes other than research and development in compliance with applicable laws.


Share this page